Data supporting "The effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on vaccine-specific responses among schoolchildren in rural Uganda: results of the POPVAC B randomised, controlled trial" – Data codebook

Persistent identifier

10.17037/DATA.00003759

Description

This dataset comprises individual-level data from participants in the POPVAC B randomised controlled trial. POPVAC B was a randomised, double-blind, placebo-controlled trial of the effect of malaria IPT with dihydroartemisinin-piperaquine (DP) on vaccine responses among schoolchildren (9-17 years) in Jinja district, Uganda (ISRCTN62041885). The aim of the trial was to comprehensively address the hypothesis that malaria infection causes suppression of responses to unrelated vaccines and that this effect can be reversed at least partially, by monthly intermittent preventive treatment (IPT) of malaria in high-transmission settings. A portfolio of vaccines, of potential benefit to the children and comprising live, inert, oral and parenteral, was provided to enable a comprehensive assessment and comparison of effects of IPT of malaria on immune response to vaccines with different characteristics.

Data access statement

To access the data, requests must be made to the PI (Professor Alison Elliott). The request will be reviewed by the PI together with the POPVAC investigator team, in consultation with the POPVAC steering committee. The request will be reviewed based on scientific value and to ensure there is no overlap with existing work. If the request is approved, before data is shared, ethics approval will need to be obtained in your host institution and a Data Transfer Agreement with the MRC/UVRI and LSHTM Uganda Research Unit must be completed.

Data codebook

The following variables are contained in the POPVAC B dataset.

Variable name Variable description Answer label Answer code Variable type
sex Participant's sex     String
    Female    
    Male    
age Participant's age in years (age placed in categories to protect participant identity)     Numeric
    Age 9 to 10 9-10  
    Age 11 11  
    Age 12 12  
    Age 13 13  
    Age 14 14  
    Age 15 to 17 15-17  
hpvexcept Is participant a girl who has previously received HPV     String
    Yes Yes  
    Not applicable NA  
hpvdoses If yes, how many doses has she received?     String
    1 1  
    2 2  
    3 3  
    Missing .  
trialarm Trial arm     String
    Dihydroartemisinin-Piperaquine DP  
    Placebo Placebo  
bcg_w0 BCG administered at week 0     String
    Yes    
    Missing .  
yf_w4 Yellow fever vaccine administered at week 4     String
    Yes    
    No    
    Missing .  
hpv_w4 HPV vaccine administered at week 4     String
    Yes    
    No    
    Missing .  
ty1d1_w4 Oral typhoid dose 1 administered at week 4     String
    Yes    
    No    
    Missing .  
ty1d2_w4 Oral typhoid dose 2 administered at week 4     String
    Yes    
    No    
    Missing .  
ty1d3_w4 Oral typhoid dose 3 administered at week 4     String
    Yes    
    No    
    Missing .  
hpv_w8 HPV vaccine administered at week 8     String
    Yes    
    No    
    Missing .  
hpv_w28 HPV vaccine administered at week 28     String
    Yes    
    No    
    Missing .  
td_w28 Tetanus-diphtheria administered at week 28     String
    Yes    
    No    
    Missing .  
td_w52 Tetanus-diphtheria administered at week 52 Yes, missing   String
    Yes    
    Missing .  
dpd1_wpre6 DP/placebo dose 1 administered 6 weeks before BCG     String
    Yes    
    No    
    Missing .  
dpd2_wpre6 DP/placebo dose 2 administered 6 weeks before BCG     String
    Yes    
    No    
    Missing .  
dpd3_wpre6 DP/placebo dose 3 administered 6 weeks before BCG     String
    Yes    
    No    
    Missing .  
dpd1_wpre2 DP/placebo dose 1 administered 2 weeks before BCG     String
    Yes    
    No    
    Missing .  
dpd2_wpre2 DP/placebo dose 2 administered 2 weeks before BCG     String
    Yes    
    No    
    Missing .  
dpd3_wpre2 DP/placebo dose 3 administered 2 weeks before BCG     String
    Yes    
    No    
    Missing .  
dpd1_w2 DP/placebo dose 1 administered at week 2     String
    Yes    
    No    
    Missing .  
dpd2_w2 DP/placebo dose 2 administered at week 2     String
    Yes    
    No    
    Missing .  
dpd3_w2 DP/placebo dose 3 administered at week 2     String
    Yes    
    No    
    Missing .  
dpd1_w6 DP/placebo dose 1 administered at week 6     String
    Yes    
    No    
    Missing .  
dpd2_w6 DP/placebo dose 2 administered at week 6     String
    Yes    
    No    
    Missing .  
dpd3_w6 DP/placebo dose 3 administered at week 6     String
    Yes    
    No    
    Missing .  
dpd1_w10 DP/placebo dose 1 administered at week 10     String
    Yes    
    No    
    Missing .  
dpd2_w10 DP/placebo dose 2 administered at week 10     String
    Yes    
    No    
    Missing .  
dpd3_w10 DP/placebo dose 3 administered at week 10     String
    Yes    
    No    
    Missing .  
dpd1_w14 DP/placebo dose 1 administered at week 14     String
    Yes    
    No    
    Missing .  
dpd2_w14 DP/placebo dose 2 administered at week 14     String
    Yes    
    No    
    Missing .  
dpd3_w14 DP/placebo dose 3 administered at week 14     String
    Yes    
    No    
    Missing .  
dpd1_w18 DP/placebo dose 1 administered at week 18     String
    Yes    
    No    
    Missing .  
dpd2_w18 DP/placebo dose 2 administered at week 18     String
    Yes    
    No    
    Missing .  
dpd3_w18 DP/placebo dose 3 administered at week 18     String
    Yes    
    No    
    Missing .  
dpd1_w22 DP/placebo dose 1 administered at week 22     String
    Yes    
    No    
    Missing .  
dpd2_w22 DP/placebo dose 2 administered at week 22     String
    Yes    
    No    
    Missing .  
dpd3_w22 DP/placebo dose 3 administered at week 22     String
    Yes    
    No    
    Missing .  
dpd1_w26 DP/placebo dose 1 administered at week 26     String
    Yes    
    No    
    Missing .  
dpd2_w26 DP/placebo dose 2 administered at week 26     String
    Yes    
    No    
    Missing .  
dpd3_w26 DP/placebo dose 3 administered at week 26     String
    Yes    
    No    
    Missing .  
dpd1_w30 DP/placebo dose 1 administered at week 30     String
    Yes    
    No    
    Missing .  
dpd2_w30 DP/placebo dose 2 administered at week 30     String
    Yes    
    No    
    Missing .  
dpd3_w30 DP/placebo dose 3 administered at week 30     String
    Yes    
    No    
    Missing .  
dpd1_w34 DP/placebo dose 1 administered at week 34     String
    Yes    
    No    
    Missing .  
dpd2_w34 DP/placebo dose 2 administered at week 34     String
    Yes    
    No    
    Missing .  
dpd3_w34 DP/placebo dose 3 administered at week 34     String
    Yes    
    No    
    Missing .  
dpd1_w38 DP/placebo dose 1 administered at week 38     String
    Yes    
    No    
    Missing .  
dpd2_w38 DP/placebo dose 2 administered at week 38     String
    Yes    
    No    
    Missing .  
dpd3_w38 DP/placebo dose 3 administered at week 38     String
    Yes    
    No    
    Missing .  
dpd1_w42 DP/placebo dose 1 administered at week 42     String
    Yes    
    No    
    Missing .  
dpd2_w42 DP/placebo dose 2 administered at week 42     String
    Yes    
    No    
    Missing .  
dpd3_w42 DP/placebo dose 3 administered at week 42     String
    Yes    
    No    
    Missing .  
dpd1_w46 DP/placebo dose 1 administered at week 46     String
    Yes    
    No    
    Missing .  
dpd2_w46 DP/placebo dose 2 administered at week 46     String
    Yes    
    No    
    Missing .  
dpd3_w46 DP/placebo dose 3 administered at week 46     String
    Yes    
    No    
    Missing .  
dpd1_w50 DP/placebo dose 1 administered at week 50     String
    Yes    
    No    
    Missing .  
dpd2_w50 DP/placebo dose 2 administered at week 50     String
    Yes    
    No    
    Missing .  
dpd3_w50 DP/placebo dose 3 administered at week 50     String
    Yes    
    No    
    Missing .  
pzq_w8 Praziquantel administered at week 8     String
    Yes    
    No    
    Missing .  
alb_w8 Albendazole administered at week 8     String
    Yes    
    No    
    Missing .  
alb_w28 Albendazole administered at week 28     String
    Yes    
    No    
    Missing .  
caa_pg_ml_baseline S. mansoni CAA concentration at baseline, pg/ml Continuous   Numeric
caa_result_baseline S. mansoni CAA result at baseline     String
    Positive Pos  
    Negative Neg  
    Indecisive indecisive  
necres_screen Necator americanus PCR result screening     String
    Positive Pos  
    Negative Neg  
    Missing .  
smct_screen S. mansoni ct value at screening Continuous   Numeric
smres_screen S. mansoni PCR result at screening     String
    Positive Pos  
    Negative Neg  
    Missing .  
ssres_screen Strongyloides stercoralis PCR result at screening     String
    Positive Pos  
    Negative Neg  
    Missing .  
pfal_ct_screen Plasmodium falciparum ct value at screening Continuous   Numeric
pfal_res_screen Plasmodium falciparum PCR result at screening     String
    Positive Pos  
    Negative Neg  
    Missing .  
pfal_ct_wk0 Plasmodium falciparum ct value at week 0 Continuous   Numeric
pfal_res_wk0 Plasmodium falciparum PCR result at week 0     String
    Positive Pos  
    Negative Neg  
    Missing .  
pfal_ct_wk4 Plasmodium falciparum ct value at week 4 Continuous   Numeric
pfal_res_wk4 Plasmodium falciparum PCR result at week 4     String
    Positive Pos  
    Negative Neg  
    Missing .  
pfal_ct_wk8 Plasmodium falciparum ct value at week 8 Continuous   Numeric
pfal_res_wk8 Plasmodium falciparum PCR result at week 8     String
    Positive Pos  
    Negative Neg  
    Missing .  
pfal_ct_wk28 Plasmodium falciparum ct value at week 28 Continuous   Numeric
pfal_res_wk28 Plasmodium falciparum PCR result at week 28     String
    Positive Pos  
    Negative Neg  
    Missing .  
pfal_ct_wk52 Plasmodium falciparum ct value at week 52 Continuous   Numeric
pfal_res_wk52 Plasmodium falciparum PCR result at week 52     String
    Positive Pos  
    Negative Neg  
    Missing .  
bcg_week0 IFN-gamma response to BCG at week 0 (SFUs per million PBMCs) Continuous   Numeric
bcg_week8 IFN-gamma response to BCG at week 8 (SFUs per million PBMCs) Continuous   Numeric
bcg_week52 IFN-gamma response to BCG at week 52 (SFUs per million PBMCs) Continuous   Numeric
tt_IgG_week28 Tetanus toxoid-specific IgG at week 28, IU/ml Continuous   Numeric
dt_IgG_week28 Diphtheria toxoid-specific IgG at week 28, IU/ml Continuous   Numeric
tt_IgG_week52 Tetanus toxoid-specific IgG at week 52, IU/ml Continuous   Numeric
dt_IgG_week52 Diphtheria toxoid-specific IgG at week 52, IU/ml Continuous   Numeric
typhi_igg_wk0 S. typhi O:LPS-specific IgG at week 0, EU/ml Continuous   Numeric
typhi_igg_wk8 S. typhi O:LPS-specific IgG at week 8, EU/ml Continuous   Numeric
typhi_igg_wk52 S. typhi O:LPS-specific IgG at week 52, EU/ml Continuous   Numeric
yfprnt_50_wk0 Yellow fever PRNT 50 titre at week 0 Continuous   Numeric
yfprnt_90_wk0 Yellow fever PRNT 90 titre at week 0 Continuous   Numeric
yfprnt_50_wk8 Yellow fever PRNT 50 titre at week 8 Continuous   Numeric
yfprnt_90_wk8 Yellow fever PRNT 90 titre at week 8 Continuous   Numeric
yfprnt_50_wk52 Yellow fever PRNT 50 titre at week 52 Continuous   Numeric
yfprnt_90_wk52 Yellow fever PRNT 90 titre at week 52 Continuous   Numeric
hpv16_wk0 HPV-16-specific IgG concentration at week 0, EU/ml Continuous   Numeric
hpv18_wk0 HPV-18-specific IgG concentration at week 0, EU/ml Continuous   Numeric
hpv16_wk8 HPV-16-specific IgG concentration at week 8, EU/ml Continuous   Numeric
hpv18_wk8 HPV-18-specific IgG concentration at week 8, EU/ml Continuous   Numeric
hpv16_wk52 HPV-16-specific IgG concentration at week 52, EU/ml Continuous   Numeric
hpv18_wk52 HPV-18-specific IgG concentration at week 52, EU/ml Continuous   Numeric